Ignite Creation Date:
2025-12-24 @ 7:03 PM
Ignite Modification Date:
2026-03-28 @ 1:28 AM
Study NCT ID:
NCT07303257
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-24
First Post:
2025-12-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options
Sponsor:
Hospices Civils de Lyon
Organization:
Study Overview
Official Title:
Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options - G-SCOPE (Glaucoma Surgery - Comparative Patient Evaluation)
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
G-SCOPE
Brief Summary:
Glaucoma, the leading cause of irreversible blindness, affects more than 60 million people worldwide and 1.3 million in France. Its treatment aims to reduce intraocular pressure, in particular by surgery when eye drops and laser treatment are insufficient.
Conventional filtering techniques and MIGS (Minimally Invasive Glaucoma Surgery), including PreserFlo® MicroShunt, pursue the same objective in terms of blood pressure, but differ in terms of their post-operative profile and tolerability.
Existing studies show similar quality of life scores between filtering and MIGS surgeries. However, no direct comparison has yet been made between trabeculectomy, non-penetrating deep sclerectomy and PreserFlo® at 3 and 6 months, making it pertinent to assess their respective effects on patients' quality of life.
Conventional filtering techniques and MIGS (Minimally Invasive Glaucoma Surgery), including PreserFlo® MicroShunt, pursue the same objective in terms of blood pressure, but differ in terms of their post-operative profile and tolerability.
Existing studies show similar quality of life scores between filtering and MIGS surgeries. However, no direct comparison has yet been made between trabeculectomy, non-penetrating deep sclerectomy and PreserFlo® at 3 and 6 months, making it pertinent to assess their respective effects on patients' quality of life.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: